SCHEMBL12416

SCHEMBL12416

Cc1cc2cc(O)ccc2o1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.57
CA9 Q16790 3/20 0.57
CA1 P00915 2/20 0.57
KDM4E B2RXH2 1/20 0.56
ALDH1A1 P00352 1/20 0.56
LMNA P02545 1/20 0.56
GLA P06280 1/20 0.56
GAA P10253 1/20 0.56
HPGD P15428 1/20 0.56
CASP1 P29466 1/20 0.56
BRCA1 P38398 1/20 0.56
CASP7 P55210 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
HSD17B10 Q99714 1/20 0.56
FLT3 P36888 1/20 0.55
ESR1 P03372 1/20 0.55
ESR2 Q92731 1/20 0.55
MCL1 Q07820 1/20 0.52
MAOB P27338 3/20 0.51
MAOA P21397 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28375021 0.84 DYRK1A (0.62) CA12CA9CA1KDM4EALDH1A1
SCHEMBL2269879 0.83 HSD17B3 (0.61) CA12CA9CA1KDM4EALDH1A1
SCHEMBL17265872 0.77 FLT3 (0.59) CA12CA9CA1KDM4EALDH1A1
SCHEMBL170369 0.77 ALDH1A1 (0.55) CA12CA9CA1ALDH1A1MAOB
SCHEMBL10791744 0.76 HSD17B3 (0.74) CA12CA9CA1KDM4EALDH1A1
SCHEMBL28047070 0.76 ALDH1A1 (0.48) KDM4EALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL9750010 0.75 GAA (0.53) CA12CA9CA1KDM4EALDH1A1
SCHEMBL1746909 0.74 DYRK1A (0.50) CA12CA9CA1KDM4EALDH1A1
SCHEMBL12267 0.74 DYRK1A (0.50) CA12CA9CA1KDM4EALDH1A1
SCHEMBL434464 0.74 MAOB (0.55) CA12CA9CA1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040231067-A1 Dyeing composition comprising a cationic tertiary para-phenylenediamine and heterocyclic coupler, methods and uses L'OREAL (FR) 2004-11-25 US claimed
EP-1428510-A1 Dyeing composition comprising a tertiary paraphenylenediamine containing a pyrrolidine, and a heterocyclic coupler or a hydroxybenzamide ; method and use L'OREAL (FR) 2004-06-16 EP claimed
US-5730962-A Depigmenting cosmetic or dermatologic composition containing a benzofuran derivative and its use in depigmentating skin L'OREAL (FR) 1998-03-24 US claimed
EP-0506549-B1 Dyeing composition for keratinous fibers containing oxidation dye precursors and hydroxybenzofurans as couplers and dyeing process making use of such a composition OREAL (FR) 1995-10-18 EP claimed
EP-0524108-B1 Use of derivatives of benzofurane as depigmentation agents in cosmetic or dermatological compositions OREAL (FR) 1995-06-07 EP claimed
US-5203875-A Hair dyes also using ortho- and para-phenylenediamines or aminophenols; colorfastness; washfastness; perspiration resistance L'OREAL (FR) 1993-04-20 US claimed
JP-5221847-A None JP disclosed
US-20250346583-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-11-13 US disclosed
EP-4613832-A1 FRAGRANCE COMPOSITION AND CONSUMER PRODUCT Takasago International Corporation (JP) 2025-09-10 EP disclosed
EP-4532012-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-04-09 EP disclosed
WO-2024096036-A1 FRAGRANCE COMPOSITION AND CONSUMER PRODUCT 高砂香料工業株式会社 2024-05-10 WO disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
WO-2023227696-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
US-5576323-A CENTRAL NERVOUS SYSTEM DISORDERS ELI LILLY AND COMPANY (US) 1996-11-19 US disclosed
EP-0658539-A1 Excitatory amino acid receptor antagonists ELI LILLY AND COMPANY (US) 1995-06-21 EP disclosed
US-5254595-A Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them ELF SANOFI (FR) 1993-10-19 US disclosed
JP-H05221847-A COMPOSITION FOR COSMETIC OR SKIN L'OREAL SA 1993-08-31 JP disclosed
US-5203875-A Hair dyes also using ortho- and para-phenylenediamines or aminophenols; colorfastness; washfastness; perspiration resistance L'OREAL (FR) 1993-04-20 US disclosed
US-3984470-A ANTIDEPRESSIVE AND ANTIAGGRESSIVE AGENTS LABAZ (FR) 1976-10-05 US disclosed
US-3931240-A ANTIDEPRESSANT, ANTIAGGRESSION LABAZ (FR) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346583-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPM4, TRPM2, TRPM6 CA12 3346/4885CA9 4241/4885CA1 1855/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A CA12 4585/4885CA9 4691/4885CA1 4543/4885
US-20040231067-A1 Dyeing composition comprising a cationic tertiary para-phenylenediamine and heterocyclic coupler, methods and uses KRT18, CDC73, PYCR1 CA12 550/4885CA9 461/4885CA1 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.